Lawrence Zaslow

Lawrence is a Director of NovoMedix. He was a cofounder and the President of BioTheryX, Inc., a clinical stage targeted protein degrader company. Lawrence was a founding Managing Director of Amphion Innovations Plc., a company that creates, operates and finances life science and technology companies in partnership with corporations, governments, universities and entrepreneurs. Mr. Zaslow was also a consultant to Amphion until July, 2009. Prior to joining Amphion, Mr. Zaslow was primarily engaged for over 25 years in raising capital for a number of start-up biotechnology companies, including the initial public offering for Celgene in 1987. Mr. Zaslow received his BA in economics from Brandeis University and his MBA in finance from the Columbia Graduate Business School.